Targeted Therapy for Gynecological Cancer
GYN eBx® | Electronic Brachytherapy
Explore GYN eBx
With a range of expertly designed applicators for both endometrial and cervical cancer for the female anatomy, simplified, targeted radiation therapy for gynecological cancer treatment in a minimally shielded setting is possible with GYN electronic brachytherapy (eBx). Our gynecological applicators provide a therapeutic dose of radiation therapy for intracavitary treatment of cancer of the uterus, cervix, endometrium and vagina, while minimizing exposure to surrounding healthy tissue such as the bladder and rectum.
By providing select gynecological cancer patients with a concentrated dose of electronic brachytherapy directly to the tumor site, our high dose, low energy technology offers an accelerated course of treatment as compared to traditional radiation therapy. By streamlining the delivery of care, GYN eBx offers increased patient compliance and satisfaction.
Targeted
A miniaturized x-ray source delivers a precise dose of radiation directly to the cancerous site.
Efficient
The Xoft System offers two different angled Colpostat sets to accommodate female anatomy with no radioactive isotopes.
Convenient
While reducing the number of required treatments, GYN eBx is most often performed as an outpatient procedure, delivered in a minimally shielded setting.
Clinically Supported
A growing body of favorable clinical data supports the use of GYN eBx in patients meeting specific selection criteria.1-7
Toxicity results after treatment with electronic brachytherapy in patients with endometrial cancer8
- 94 patients
- Treated from September 2015 to September 2017
- Median follow-up: 11 months
- Preliminary results show targeted approach reduces toxicity to organs at risk.
lr-192
Xoft 50 kV
The Xoft System is able to precisely target cancer cells and spare surrounding healthy tissue, resulting in a significant reduction in the radiation dose that reaches organs at risk. Our early results with this targeted technology are very promising, and we are pleased to offer this valuable treatment option to appropriately selected patients with endometrial and cervical cancer.
– Agustina Mendez Villamon, MD
Radiation Oncologist
Miguel Servet University Hospital, Zaragoza, Spain
Discover our core line of GYN eBx products
Learn More>
Axxent Controller
The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body.
Vaginal Applicators
The Axxent® vaginal applicators are a key component of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, empowering targeted brachytherapy in the vagina and rectum.
Cervical Applicator
The Axxent cervical applicator is a key component of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, empowering targeted intracavitary treatment of cancer of the uterus, cervix, endometrium and vagina.
References: 1. S Lozares, et al. Dosimetric Comparison of Brachytherapy Sources for High Dose-Rate Treatment of Endometrial Cancer: Electronic Brachytherapy, 192Ir, and 60Co Sources. Presented at AAPM 2017. 2. S Lozares, et al. Comparison of brachytherapy sources of endometrial cancer: Electronic brachytherapy source and 192Ir. Presented at ESTRO 2017. 3. A Villamon, et al. Acute toxicity results after treatment with Xoft Axxent Electronic Brachytherapy (XB) in patients with endometrial or cervical cancer. Presented at ESTRO 2017. 4. J Thompson. Feasibility of Cervical Brachytherapy with a Novel 50 kV Electronic Brachytherapy Source. Presented at RSNA 2014. 5. M Kamrava, et al. Electronic brachytherapy for postsurgical adjuvant vaginal cuff irradiation therapy in endometrial and cervical cancer: A retrospective study. Brachytherapy 12 (2013) 141-147. 6. W Dooley, et al. Use of electronic brachytherapy to deliver postsurgical adjuvant radiation therapy for endometrial cancer: a retrospective multicenter study. OncoTargets and Therapy 2010:3 197-203. 7. Dickler, et al. A dosimetric comparison of Xoft Axxent Electronic Brachytherapy and iridium-192 high-dose-rate brachytherapy in the treatment of endometrial cancer. Brachytherapy 2008:5. 8. A Villamon, et al. Toxicity results after treatment with electronic brachytherapy in patients with endometrial cancer. Presented at ESTRO37 (2018).
Products
Resources
Precision therapy. Personalized care.
© Xoft, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.